INSTANTPEPTIDES

Methylene Blue: Phenothiazine Redox Compound Research Overview

Methylene Blue is a synthetic phenothiazine compound with a long history in chemistry and biology dating to 1876, when Heinrich Caro first synthesized it. The compound has unique redox properties that have made it valuable across multiple research contexts: as a histological stain, as a redox indicator, and as a probe of mitochondrial electron transport. This page summarizes the published research applications.

Last reviewed: 2026-05-11· Instant Peptides Research Team
Research-use reference only. The content below summarizes published preclinical and in vitro research. Not for human or animal consumption, diagnostic, or therapeutic use. Information is provided as an educational resource for qualified research professionals.

Background

Methylene Blue (chemical name: 3,7-bis(dimethylamino)-phenothiazin-5-ium chloride) was first synthesized in 1876 and was the first fully synthetic drug used in medicine, predating most modern pharmacology. Its applications have included histological staining (Romanowsky stains), microbiological detection methods, and redox indicator applications in chemistry.[1]

In modern biological research, Methylene Blue is a tool compound for studying mitochondrial electron transport, cellular redox state, and several specific signaling pathways. The compound's unique chemistry — a stable redox couple (methylene blue ↔ leucomethylene blue) at biologically relevant potentials — makes it useful for these applications.[2]

Methylene Blue is studied as a research reference compound. While clinical applications exist with approved indications in specific therapeutic contexts (e.g., methemoglobinemia), research-grade material is supplied for laboratory research only.

Chemistry & Structure

Methylene Blue structural features:

  • Chemical name: 3,7-bis(dimethylamino)-phenothiazin-5-ium chloride
  • Molecular formula: C₁₆H₁₈ClN₃S (with one water of crystallization in some forms)
  • Molecular weight: approximately 319.85 g/mol (anhydrous)
  • Color: characteristic dark blue solid; intense blue in aqueous solution at typical concentrations
  • Structural class: phenothiazine derivative

Redox couple

Methylene Blue's defining chemistry is its reversible reduction to leucomethylene blue (the colorless reduced form). The redox potential at physiological pH is approximately +11 mV, placing it within the operating range of cellular electron transport machinery. This is why the compound interacts with biological redox systems.[2]

The compound can serve as an alternative electron acceptor or donor in cellular environments, allowing it to bypass certain electron transport blockages — a property that underlies many of its research applications.

Research Applications

Methylene Blue research spans biochemistry, cell biology, and neuroscience.

Mitochondrial electron transport research

Cell-based and isolated mitochondria preparations have used Methylene Blue as a probe of electron transport function. The compound can shuttle electrons across complex inhibitor blockages, providing a research tool for dissecting which transport chain components contribute to specific phenotypes.[3]

Nitric oxide pathway research

Methylene Blue inhibits guanylate cyclase, the enzyme that produces cGMP downstream of nitric oxide signaling. This makes the compound a research tool for dissecting NO-dependent vs NO-independent signaling in cell-based and vascular preparation studies.[4]

Neuroprotection research

Rodent models of neurodegeneration have examined Methylene Blue in experimental arms targeting mitochondrial dysfunction. The compound's ability to enter mitochondria and influence electron transport is the basis for these research lines.[5]

Tau protein aggregation research

Methylene Blue (and derivatives) have been examined in preclinical research on tau protein aggregation, which is associated with several neurodegenerative conditions. These studies are conducted in cell-based and animal model systems.[6]

Stability & Handling

Methylene Blue is chemically stable under normal conditions. Standard organic compound handling applies.

Storage

Supplied in capsule form (60-count, 20mg per capsule). Storage at room temperature in a cool, dry place. The compound itself is stable to standard conditions but should be kept dry to prevent moisture uptake.

Quality verification

Quality verification includes HPLC for purity (target greater than or equal to 99 percent for USP-grade material), UV-visible spectroscopy for identity confirmation (characteristic absorption at 664 nm), and trace impurity analysis. Each batch of Instant Peptides Methylene Blue ships with a full Certificate of Analysis.

Available Research Material

Instant Peptides supplies Methylene Blue in 20mg capsules (60-count bottle) as a research reference compound. Material is supplied to qualified research professionals. Not for human or animal consumption.

View the product page for current pricing and the Certificate of Analysis for the active batch.

Available Research Material

Methylene Blue

Lyophilized synthetic reference compound. Independently tested for purity by HPLC and mass spectrometry. Full Certificate of Analysis included.

View product details

References

  1. 1.Schirmer RH, Adler H, Pickhardt M, Mandelkow E. 'Lest we forget you — methylene blue …' Neurobiology of Aging. 2011. PMID: 21601951
  2. 2.Tucker D, Lu Y, Zhang Q. From Mitochondrial Function to Neuroprotection — an Emerging Role for Methylene Blue. Molecular Neurobiology. 2018. PMID: 28828697
  3. 3.Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB Journal. 2008. PMID: 18171693
  4. 4.Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochemical Pharmacology. 1993. PMID: 7682557
  5. 5.Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Progress in Neurobiology. 2012. PMID: 22078297
  6. 6.Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proceedings of the National Academy of Sciences. 1996. PMID: 8901664

Related Research